Esperion Therapeutics, Inc. (ESPR) Rating Reiterated by Bank of America Corporation
Esperion Therapeutics, Inc. (NASDAQ:ESPR)‘s stock had its “neutral” rating reiterated by Bank of America Corporation in a note issued to investors on Friday, MarketBeat.com reports.
Other equities analysts also recently issued research reports about the company. UBS AG reiterated a “buy” rating and set a $57.00 price target (up previously from $52.00) on shares of Esperion Therapeutics in a research report on Tuesday, June 27th. Stifel Nicolaus reiterated a “buy” rating and set a $70.00 price target (up previously from $60.00) on shares of Esperion Therapeutics in a research report on Thursday. Zacks Investment Research downgraded Esperion Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday. Jefferies Group LLC upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating and decreased their target price for the company from $85.00 to $55.00 in a research report on Tuesday. Finally, Needham & Company LLC raised their target price on Esperion Therapeutics from $58.00 to $72.00 and gave the company a “positive” rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company. Esperion Therapeutics has a consensus rating of “Hold” and an average price target of $41.16.
Esperion Therapeutics (NASDAQ:ESPR) traded down 0.2164% on Friday, reaching $48.0358. The company had a trading volume of 481,647 shares. The stock’s market capitalization is $1.09 billion. The stock’s 50 day moving average is $46.88 and its 200-day moving average is $34.99. Esperion Therapeutics has a 1-year low of $9.40 and a 1-year high of $57.38.
Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.67) by $0.25. During the same period in the prior year, the firm posted ($0.62) earnings per share. On average, equities analysts predict that Esperion Therapeutics will post ($7.29) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/11/esperion-therapeutics-inc-nasdaqespr-research-coverage-started-at-bank-of-america-corporation.html.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ESPR. Bank of New York Mellon Corp boosted its position in Esperion Therapeutics by 29.4% in the first quarter. Bank of New York Mellon Corp now owns 104,603 shares of the biopharmaceutical company’s stock valued at $3,693,000 after buying an additional 23,740 shares during the last quarter. Bailard Inc. bought a new position in Esperion Therapeutics during the first quarter valued at approximately $1,448,000. UBS Asset Management Americas Inc. bought a new position in Esperion Therapeutics during the first quarter valued at approximately $6,608,000. Ameriprise Financial Inc. bought a new position in Esperion Therapeutics during the first quarter valued at approximately $1,498,000. Finally, Russell Investments Group Ltd. bought a new position in Esperion Therapeutics during the first quarter valued at approximately $961,000. 85.20% of the stock is owned by hedge funds and other institutional investors.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.